^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MCLA-145
i
Other names: MCLA-145, MCLA145, MCLA 145
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merus
Drug class:
PD-L1 inhibitor, CD137 agonist
Related drugs:
8d
MCLA-145-CL01: A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies (clinicaltrials.gov)
P1, N=72, Completed, Merus N.V. | Active, not recruiting --> Completed | N=238 --> 72 | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Dec 2025 --> Nov 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • MCLA-145
3ms
MCLA-145-CL01: A Study of Bispecific Antibody MCLA-145 in Patients with Advanced or Metastatic Malignancies (clinicaltrials.gov)
P1, N=238, Active, not recruiting, Merus N.V. | Recruiting --> Active, not recruiting | N=118 --> 238 | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • MCLA-145
3years
Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors (ESMO-IO 2021)
Legal entity responsible for the study The authors, Incyte Corporation, and Merus NV. Funding This study was funded by Incyte Corporation, Wilmington, DE, USA, and Merus NV, Utrecht, Netherlands.
P1 data
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
MCLA-145
Share via
